pros and cons of glp-1 agonist Advantages and disadvantages lixisenatide therapy TrimRX | GLP-1 vs GIP:
Description
No significant differences were noted in the secondary outcomes post-weighting between these two groups, with all results consistent across multiple sensitivity analyses
These latter AEs were more common in the anti-ActA and combination groups, and while these are difficult to assess in rodents and primates, we did not observe any of these in any of our preclinical in vivo studies
Oncol Lett
& Smith, T
10.7501/j.issn.1674-6376.2020.03.037 35 EdgardZ.JeanL
PMID: 73 CurradoDSaracinoFDe VincenzoFTrunfioFMarinoAKunLet al
